Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRONG-HF rapid optimization of guideline-directed heart failure therapy
2018-000486-37Phase 4Completed
- Sponsor
- Heart Initiative
- Start
- Dec 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of carvedilol and canrenoic acid in Acute Heart Failure (AHF) (2 arms), sponsored by Heart Initiative. Primary endpoint: 180-day all-cause mortality or heart failure readmission. Started Dec 2018; status: completed.
02
Drugs
carvedilolcanrenoic acid
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2018-000486-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000486-37.